Income Statement
CHEMOMAB THERAPEUTICS LTD.
CMMB
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
28.53 | 12.37 | 11.71 | 22.90 |
|
Research & Development
|
16.98 | 6.33 | 3.78 | 13.30 |
|
Selling, General & Administrative
|
11.56 | 6.03 | 7.18 | 6.25 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-28.53 | -12.37 | -11.71 | -22.90 |
|
Non-Operating Income
|
0.35 | - | - | -50.02 |
|
Interest Income
|
- | - | - | - |
|
Interest Expense
|
- | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - |
|
Income Before Tax
|
-28.18 | 12.48 | 11.61 | 27.12 |
|
Income Tax Expense
|
-0.53 | - | - | 54.25 |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-27.65 | -12.48 | -11.61 | -27.12 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-28.53 | -12.37 | -11.71 | -22.90 |
|
Earnings Per Share (Basic)
|
0.12 | - | - | - |
|
Diluted EPS
|
0.12 | - | - | - |
|
Weighted Average Shares
|
227.59 | - | - | - |
|
Diluted Weighted Avg Shares
|
227.59 | - | - | - |
|
Comprehensive Income
|
- | - | - | 27.12 |